We are live on
!
Find out more
FCMI
Foresite Capital Management IV Portfolio holdings
AUM
$237M
1-Year Est. Return
107.53%
This Fund
S&P 500
This Quarter
Est. Return
+8.39%
1 Year Est. Return
+107.53%
3 Year Est. Return
+149.4%
5 Year Est. Return
+13.8%
10 Year Est. Return
–
AUM
$241M
AUM Growth
+$98.5M
(+69%)
Cap. Flow
+$97.2M
Cap. Flow
% of AUM
40.3%
Top 10 Holdings %
Top 10 Hldgs %
82.6%
Holding
19
New
6
Increased
8
Reduced
3
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Insmed
INSM
|
+$24.2M |
| 2 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$19.1M |
| 3 |
Arcus Biosciences
RCUS
|
+$10.8M |
| 4 |
ALDR
Alder Biopharmaceuticals
ALDR
|
+$8.65M |
| 5 |
Arbutus Biopharma
ABUS
|
+$7.07M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$3.03M |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
+$1.77M |
| 3 |
uniQure
QURE
|
+$1.64M |
| 4 |
Denali Therapeutics
DNLI
|
+$1.48M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Insmed
INSM
$23.2B
| $40.5M | 16.8% |
1,799,225
+919,315
| +104% | +$24.2M |
|
|
2
Ascendis Pharma A/S
ASND
$16.7B
| $31.1M | 12.89% |
475,419
-53,924
| -10% | -$3.03M |
|
|
CBAY
3
DELISTED
Cymabay Therapeutics
CBAY
| $27.4M | 11.37% |
2,111,869
-142,633
| -6% | -$1.77M |
|
|
BHVN
4
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $21.9M | 9.09% |
851,200
+637,765
| +299% | +$19.1M |
|
|
MYOK
5
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $19.1M | 7.93% |
391,955
+82,598
| +27% | +$4.29M |
|
|
IMMU
6
DELISTED
Immunomedics Inc
IMMU
| $15.7M | 6.5% |
1,073,272
| – | – |
|
|
7
uniQure
QURE
$2.68B
| $13.2M | 5.46% |
560,073
-75,161
| -12% | -$1.64M |
|
|
ALDR
8
DELISTED
Alder Biopharmaceuticals
ALDR
| $10.6M | 4.38% |
830,919
+598,010
| +257% | +$8.65M |
|
|
9
Arcus Biosciences
RCUS
$3.57B
| $10M | 4.16% |
+650,000
| New | +$10.8M |
|
|
OPTN
10
DELISTED
OptiNose
OPTN
| $9.68M | 4.01% |
32,240
+2,240
| +7% | +$620K |
|
|
ALDR
11
PUT
DELISTED
Alder Biopharmaceuticals
ALDR
| $7.9M | 3.28% |
+450,000
| New | +$6.51M |
|
12
Aclaris Therapeutics
ACRS
$730M
| $7.53M | 3.12% |
429,551
+177,615
| +71% | +$3.76M |
|
|
13
Arbutus Biopharma
ABUS
$865M
| $7.43M | 3.08% |
1,485,245
+1,334,653
| +886% | +$7.07M |
|
|
14
PUT
Insmed
INSM
$23.2B
| $6.8M | 2.82% |
+300,000
| New | +$7.9M |
|
|
MYOK
15
PUT
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $4.9M | 2.03% |
+100,000
| New | +$5.2M |
|
16
Rhythm Pharmaceuticals
RYTM
$7B
| $3.98M | 1.65% |
200,000
+25,000
| +14% | +$664K |
|
|
RARX
17
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $2.39M | 0.99% |
+450,000
| New | +$3.22M |
|
18
Solid Biosciences
SLDB
$771M
| $1.05M | 0.44% |
+9,355
| New | +$3.16M |
|
|
19
Denali Therapeutics
DNLI
$3.67B
| – | – |
-94,666
| Closed | -$1.48M |
|
Similar funds
BCM
ICMM
AG
FL
TS
EA
PVM
MFA
Foresite Capital Management IV's Q1 2018 Portfolio in Review
As of Q1 2018, Foresite Capital Management IV held 19 positions worth $241M, up 69% from $143M the previous quarter. Its ten largest holdings account for 83% of the portfolio.
Foresite Capital Management IV deployed $97.2M of net new capital in Q1 2018, opening 6 new positions and adding to 8 existing holdings. Its largest new stake was Arcus Biosciences: 650,000 shares worth $10M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 88% a quarter earlier.
On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $3.03M trimmed.
- Foresite Capital Management IV's largest Q1 2018 buy was Arcus Biosciences: 650,000 shares worth $10M.
- Foresite Capital Management IV added most to Insmed in Q1 2018, an estimated $24.2M increase.
- Foresite Capital Management IV's biggest Q1 2018 reduction was Ascendis Pharma A/S, cutting an estimated $3.03M.
- Foresite Capital Management IV fully exited Denali Therapeutics in Q1 2018, selling an estimated $1.48M.
- Foresite Capital Management IV's ten largest holdings make up 83% of its $241M portfolio in Q1 2018.
- Foresite Capital Management IV opened 6 new positions and closed 1 in Q1 2018.
- Foresite Capital Management IV's portfolio value rose 69% quarter-over-quarter to $241M.
Based on Foresite Capital Management IV's 13F filing for Q1 2018, filed 15 May 2018.